AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

– First patients with COVID-19 enrolled in the REVIVAL Phase III study – COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall – RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan […]

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

– Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study – Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America   Utrecht, The Netherlands, 12 November 2020 – AM-Pharma B.V., an emerging leader focused on the […]

AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board

Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board. With over 20 years of experience in pharmaceutical development, Dr. Jain most recently was Senior Vice President and Chief Medical Officer at […]

AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of […]

AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

€23m (US$25.5m) equity provided mainly by US-based Cowen Healthcare Investments €24m (US$26.5m) finance facility provided by the European Investment Bank (EIB) Increased funding allows for finalization of all Marketing Authorization Application preparation activities Utrecht, The Netherlands, 31 March 2020 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of […]

AM-Pharma vergroot met extra €47 miljoen de financiering voor klinische fase III-registratiestudie met Nederlands kandidaatmedicijn tegen acuut nierfalen tot €163 miljoen

Tegen de aandoening bestaat mondiaal nog geen goedgekeurde therapie (700.000 overlijdens per jaar) €23 miljoen hoofdzakelijk afkomstig van het Amerikaanse Cowen Healthcare Investments €24 miljoen financieringsfaciliteit verstrekt door de Europese Investeringsbank (EIB) Beoogde klinische studie met 1.400 patiënten grootste ooit op zijn gebied (>100 ziekenhuizen, 12 landen) Financiering voldoende tot aan aanvraag van marktgoedkeuring voor […]

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

Juliane Bernholz has joined as Chief Operating Officer Kristie Bass has joined as VP Clinical Operations Bunnik, The Netherlands, 1 October 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today […]

AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI) AKI […]

AM-Pharma haalt €116 miljoen ($133 miljoen) financiering op voor fase III registratie-studie met kandidaat-medicijn tegen acuut nierfalen (AKI)

Grootste biotech VC financieringsronde ooit in Nederland, geleid door nieuwe investeerders LSP en Andera Partners met deelname van bestaande investeerders Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures en Gilde Healthcare Opbrengst bestemd voor internationale Fase III-registratie-studie met ‘recombinant humaan Alkalische Fosfatase’ (recAP) bij 1.400 patiënten met sepsis (bloedvergiftiging) -geassocieerd acuut nierfalen […]